The diagnosis of prostate cancer has undergone an unprecedented recent increase, while mortality has increased much more slowly.
Introduction
The incidence of prostate cancer has recently experienced an unprecedented increase in diagnoses while prostate cancer mortality has risen much more slowly. 1±4 The concurrent increases in prostate needle biopsy procedures and PSA testing 4, 5 suggest that the epidemic of prostate cancer diagnoses results from increased use of prostatespeci®c antigen (PSA) screening. If true, this indicates a strikingly rapid diffusion of the PSA screening technology, despite ongoing uncertainty and active debate over its value 6±8 and con¯icting authoritative recommendations from medical organizations.
9±11
One partial explanation may be the in¯uence of wellpublicized but inconclusive medical research. The Group Health Cooperative (GHC) of Puget Sound, a large health maintenance organization in western Washington, reported more than a three-fold increase in PSA blood tests ordered immediately following the report in the New England Journal of Medicine of a program of PSA screening by Catalona et al. 12 This study, which concluded that the screening program`identi®es patients at high risk for prostate cancer,' lacked an unscreened asymptomatic control group. 13 To investigate the quantitative relation-ship between this report and increased diagnosis of prostate cancer, we examined diagnoses of prostate cancer from 1987 through January, 1992, in the Health Professionals Follow-up Study (HPFS), a prospective nationwide cohort study of a medically-sophisticated population whose experience might provide an early indication of changing patterns of medical care in the United States.
Subjects and methods
The study population
In 1986, we formed the HPFS cohort to study of the causes of cancer and heart disease in men. 14, 15 The source population was based on lists provided by several US professional organizations of health care providers. Over 150 000 men were sent the baseline questionnaire, 51 529 responded. The ®nal study population consisted of dentists (58%), optometrists (7%), osteopaths (4%), podiatrists (3%), pharmacists (8%) and veterinarians (20%), aged 40±75 y in 1986, residing in all 50 US states, over 95% were Caucasian. The 1986 questionnaire included information on age, marital status, ancestry, use of medications, disease and other medical history, level of physical activity, height and weight, and typical diet. The responses were received throughout the year in 1986, and early in 1987.
Identi®cation of cases of prostate cancer
In 1988, 1990 and 1992, we mailed follow-up questionnaires to all study participants; on each of these forms we asked the participant whether he had a diagnosis of prostate cancer during the previous two years. Each follow-up cycle included up to six mailings of the questionnaire to nonrespondents, including two certi®ed mailings, yielding a response rate of 94% through 1992. Nonresponse is unlikely to distort our results because of the high followup response rate. Moreover, because early prostate cancer, which accounts for the great majority of the prostate cancers we identi®ed, is rarely associated with substantial debilitation, non-response is unlikely to be associated with our study endpoints. When the subject (or next of kin for decedents) reported a diagnosis of prostate cancer, we sought permission to obtain hospital records and pathology reports. From 1986 to the end of this study period, January 31, 1992, we documented 812 new cases of prostate cancer. Of these, 708 cases including 41 deaths (87.2%) were con®rmed by medical records, 91 men (11.2%) from whom we did not have medical records provided additional information regarding the diagnosis and treatment and 13 men (1.6%) could not be recontacted. When we obtained medical records and pathology reports, a diagnosis of adenocarcinoma of the prostate was con®rmed in 99% of the cases. Because of this high con®rmation rate, we analyzed all cases of men who reported a diagnosis of prostate cancer.
Study physicians classi®ed prostate cancers based on the best available medical information based on the extent of tumor progression after diagnosis and initial therapy. Thus, patients with radical prostatectomy, but not radiotherapy, had the opportunity to be`upstaged' if surgical specimens showed tumor extension outside the prostate or involved pelvic lymph nodes.`Organ-con®ned' tumors were limited to the prostate gland,`regionally-advanced' tumors which had invaded through the capsule without evidence of metastasis, and`metastatic' tumors which had evidence of spread to regional lymph nodes or other organs.
Data analysis
For these analyses, we excluded men from the base population of 51 529 who reported cancer at baseline (other than non-melanoma skin cancer) or who did not adequately complete the questionnaire, leaving 47 894 men eligible for follow-up. We examined prostate cancer incidence rates, de®ned as new prostate cancer cases divided by the number of person-years of follow-up, between January, 1986 and January 31, 1992. To avoid potential bias by classifying as without cancer undiagnosed patients exhibiting signs and symptoms of cancer, the date of diagnosis was de®ned as that of the ®rst abnormality suggesting cancer. Thus, the date of diagnosis for patients biopsied after elevated PSA levels was the date of the PSA test, rather than that of the subsequent biopsy revealing prostate cancer. Because of the sharp rise in prostate cancer with age, we used age-standardized rates for comparisons, using direct standardization 16 to the age distribution of a single standard population, the HPFS population in 1989, the mid-point of this study. We categorized age into ®ve-year categories.
We also compared rates from our cohort with 1985± 1989 incidence rates from the SEER program. 17 In this case, we used indirect standardization, whereby the standard set of age-speci®c SEER rates are applied to the agedistribution of the HPFS population to calculate an expected number of cases in a population of our size and age distribution if it had the same age-speci®c rates as occurred in the SEER areas.
Poisson regression techniques 18 were used to calculate the predicted rates shown in Figure 2 with Splus statistical software. 19 Based upon the monthly stage-speci®c rates between 1987 and 1992, a Poisson regression model was identi®ed which maximized the goodness-of-®t of the model as measured by the deviance statistic, and which conformed to a priori expectations about the dependency of the rates upon stage, age and calendar time. The 95% con®dence intervals for the rates predicted from this model were calculated in the usual manner from the estimated values of the parameters for the model given above and a variance derived by a straightforward application of the multivariate delta method 20 and the variance-covariance matrix for the parameter estimates from the model given above. The formula and details regarding its derivation may be obtained from one author (DS) upon request. Two-tailed hypothesis tests, such as that organ-con®ned disease rates did not change appreciably after March, 1991, were based upon c 2 statistics formed from the square of the corresponding estimated model parameter divided by its variance.
Results
The age-standardized rates of prostate cancer categorized by the extent of progression from 1987±1992 are shown in Figure 1 . (We excluded 1986 since the baseline question-naires were returned throughout that year yielding insuf®cient follow-up time). The incidence rates of organcon®ned disease were relatively stable from 1987±1989 and then increased dramatically during 1990 and 1991. By 1991, the rate for organ-con®ned diseased was about fourfold that in 1987. A suggestive increase in regionallyadvanced disease (penetrating through the capsule) was noted during 1991 but not during 1990. There was no indication of any rise in metastatic prostate cancer from 1987±1991, during which the standardized rates varied little (52 per 10 5 person-years in 1987 to 53 in 1991). We used Poisson regression to model the rate of prostate cancer by stage over consecutive months from January, 1987, to January, 1992, the ®nal month for which we had complete data. A priori, we had established that the model would include variables for age category (using less than 60 y as the reference category), month (since January, 1987), and stage (using metastatic cancer as the reference category). We also included interactions terms between organ-con®ned and regionally-advanced stage and month, which allowed us to examine any changes in rates over time by stage. This basic model indicated a highly signi®cant positive association with month since January, 1987, (P`0.0001) for organ-con®ned disease, a modest increase in regionally-advanced prostate cancer, and no increase in metastatic cases.
We explored whether adding other time variables improved the ®t of the model. Because of a previously reported increase in rates from 1989±1990, 3 we added a term for rates beginning January, 1990, to the basic model. This term did not improve the ®t of the model, indicating not that rates were not increasing after January, 1987 but that adding this speci®c term did not appreciably improve the basic model, which already had a variable for an increasing trend over the entire study period.
Based on the reported increase in orders for PSA testing following an April, 1991, report in the New England Journal of Medicine advocating its use in screening, 12, 13 we added an indicator term to denote the time period after March, 1991 to the basic model. The coef®cient for this term was highly signi®cant for organ-con®ned tumors (P`0.0001) and regionally-advanced tumors (P 0.01), but not metastatic (Stage D) tumors. Adding this terms eliminated the signi®cance of the interaction terms for stage and month, which indicated most of the overall trend of increasing organ-con®ned and regionallyadvanced cases over the entire study period was due to the further increase beginning after March, 1991. Using terms for months prior to and after March, 1991 yielded models that did not predict the data as well (based on residual deviance). Thus, we concluded that the best ®tting model included age, stage, month since January, 1987, and, for organ-con®ned and regionally-advanced tumors, diagnosis after March, 1991. The results from this model are displayed graphically in Figure 2 . This model estimates the immediate increase in the rates of diagnosis after March, 1991, for organ-con®ned tumors as 86% (95% CI: 36±256%) and for regionally-advanced tumors as 73% (95% CI: 12±267%) relative to metastatic tumor rates at the same time.
The rise in organ-con®ned cancers over time was dramatic. From January, 1987 to December, 1989 the median number of organ-con®ned cases of prostate cancer diagnosed per month was 4 (range 0±7), from January, 1990 through March, 1991, the median was 7 (range 1±12), and from April, 1991 to January 31, 1992, the median was 14 (range 8±24). In January, 1992, 24 cases were diagnosed. Of the 60 months represented in the study period, the 8 highest values for cases per month occurred in the last 10 months beginning April, 1991.
We examined how these diagnostic rates corresponded to rates using SEER data (Table 1) . From 1986±1989, HPFS rates were quite similar to SEER rates during a similar time period (1985±1989). From January, 1990 to March, 1991, when the rates began to rise, a 33% excess in rates occurred compared to the 1985±1989 SEER rates, Finally, beginning April, 1991, an elevation of about 160% in rates was noted across all age groups, including men 75±79 y of age. As demonstrated by Figures 1 and 2 , this rise is due almost entirely to organ-con®ned disease.
The proportion and number of tumors diagnosed by transurethral resection of the prostate (TURP) decreased from 1986±1991. In 1991, only 5% of all cancers were diagnosed due to TURPs. The actual number of radical prostatectomies which included lymph node dissection increased markedly over time (1988: 57; 1989: 45; 1990: 71; 1991±92: 147) while the proportion of all prostatectomies which included lymph node dissection remained stable (62, 51, 57 and 62%, respectively). Therefore, it is unlikely that decreased opportunities for upstaging apparently organ-con®ned (stage B) cancers by surgical documentation of tumor penetration through the capsule (stage C) or into regional lymph nodes (stage D1) caused any of the shift to lower tumor stage at diagnosis from 1986±1991.
Discussion
We found a striking increase of almost four-fold in the age-standardized incidence of prostate cancer in men studied prospectively in the Health Professionals Follow-up Study from 1987±1991. The sharply increased incidence occurred almost exclusively in organ-con®ned (localized) prostate cancer and was evident in 1990 and 1991, consistent with diagnosis as a result of screening of asymptomatic patients.
Based on incidence rates, the study period appeared to fall into three areas. In the ®rst era, 1987±89, the incidence Figure 1 Age-standardized incidence rates of prostate cancer by extent of progression at diagnosis.
Early prostate cancer epidemic E Giovannucci et al of prostate cancer remained essentially stable. From January, 1990 to March, 1991, rates for organ-con®ned prostate cancer rose substantially. Finally, from April, 1991 to January, 1992, an additional sharp increase in organcon®ned tumors occurred, along with a lesser increase in regionally-advanced tumors. The rise beginning in April, 1991, was of particular interest to us because of our impression that the appearance of the widely publicized study by Catalona et al 13 supporting the use of prostate speci®c antigen (PSA) screening, which was published in the New England Journal of Medicine in April, 1991, had a signi®cant impact on clinical practice. If such an effect occurred, it would be expected to occur earlier in this highly-aware population of health professionals than in the general US population. Finding an increase in the diagnosis of early prostate cancer immediately after the publication of a well-publicized study supporting screening does not prove a causal relationship; other factors may have played a role, and the association may be due to chance. The evidence of a smaller, earlier increase in the rate of diagnosis of earlystage prostate cancer throughout the study period suggests a growing practice of prostate cancer screening, probably based in part on other favorable reports on PSA screening. The aging of the study population had no effect on our rates, which were age-adjusted.
Our data are consistent with other recent reports of trends in prostate cancer incidence, all of which show substantial increases. 1, 4, 5 Our results are unique in documenting a sudden acceleration in these trends since Figure 2 Age-standardized observed and predicted rates for tumors diagnosed from 1987 through January, 1992, by extent of disease at diagnosis.
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April, 1991. Because our study population is comprised of health professionals, they are a priori likely to have heightened awareness of important medical issues. As a result, their experience may provide an early indication of changes in medical practice which extend later to a wider population. It is interesting to note that the incidence of prostate cancer appeared to peak in the US in 1992, falling in 1993 and 1994. 21, 22 The trend was so abrupt and unexpected that the American Cancer Society made an unprecedent midyear reduction in its estimated prostate cancer incidence for 1997. 23 This phenomenon of a sharp rise in incidence associated with increased screening followed by a rapid decline may be explained by`clearing' of prevalent cases by prior screening or by decreased use of screening.
While the sequence of the publication of the Catalona report supporting screening followed by an abruptly increased rate of diagnosis is suggestive, a causal association requires a plausible intervening mechanism. Either physicians or patients could initiate the idea of PSA screening. A published scienti®c paper could affect clinical practice in several ways: directly by in¯uencing those who read and accept the conclusions, or indirectly through changed recommendations of professional organizations or in¯uence on patients and physicians through mass media description of the published article. The publication of this well-publicized study favoring screening, although not de®nitive evidence, may have reinforced favorable beliefs or undermined doubts regarding screening's ef®-cacy by physicians and patients. In the litigious American medicolegal environment, a well-publicized study favoring screening may make physicians who do not adopt it feel vulnerable to lawsuit. A cautionary editorial identifying the value of the Catalona article but also noting the remaining research issues, which might have moderated its reception, including the sense of potential medicolegal obligation, did not accompany it. As a result, the perspective of an independent, informed peer reviewer was unavailable to the article's medical readership or the popular press. Although ®ve other reviews of screening with PSA for prostate cancer appeared in the previous six months in general medicine, 24, 25 oncology, 26 and urology 27,28 journals, none recommended its immediate widespread adoption. The short time period between the article's publication and the increased rate of prostate diagnosis precludes intervening variables such as recommendations of professional organizations. In fact, recommendations by the American College of Radiology, the American Urologic Association and the American Cancer Society occurred in 1992. 9 Non-physician health care professionals, which comprise our population, are highly attuned to important medical developments. However, only 4% of the cohort, the osteopaths, are physicians, and thus professionally trained to assess published medical reports independently. As a result, nearly all must rely largely on interpretations of the primary data in the mass media. There is evidence that an intentional mass media publicity campaign directed at the public may affect medical practice substantially. A campaign in Italy to inform the public of current, more limited indications for hysterectomy resulted in a 33% reduction in hysterectomies. 29 
Wennberg and coworkers
30±33 have shown that medical practice patterns are most variable when the medical indications are least clear. While many investigators are strongly convinced of the value of PSA screening, the issue remains unresolved and is the focus of much research. A recently-published decision analysis found little bene®t from screening, 6 and the National Cancer Institute of the United States has initiated a large randomized trial of screening for prostate cancer. 34 Evidence suggests highly variable practice patterns in the diagnosis and treatment of prostate cancer. Recent studies demonstrated four-fold variation in the rate of increase in prostate cancer incidence rates between 1983 and 1989 among Surveillance, Epidemiology, and End Results (SEER) program areas, 1 and ®ve-fold differences in rates of radical prostatectomy between states 35 and SEER program areas. 1 Authoritative recommendations for PSA screening for prostate cancer con¯ict. This context of uncertainty is an ideal situation for non-medical factors to in¯uence medical practice patterns. Our results suggest, ironically, that a well-publicized medical article which is not de®nitive can be seen as a`non-medical factor' in¯uencing the adoption of an important medical practice, PSA screening for prostate cancer.
Conclusion
The impact of the media on public opinion is neither predictable nor easily controlled. Our results suggest that publicity accompanying research published in the most in¯uential medical and scienti®c journals, often cultivated to improve public awareness of important medical advances, 36, 37 may also amplify the impact of medical research whose interpretation is ambiguous. When a de®nitive report is published, mass media publicity may accelerate bene®cial change in medical practice. When the report is inconclusive and unaccompanied by editorial signals for cautious interpretation, its impact may be disproportionate and unexpected.
